The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s pharmaceutical contract development and manufacturing organization (CMO) market report forecasts the pharmaceutical contract development and manufacturing organization (CMO) market size to grow to $196.53 Billion by 2027, with a CAGR (compound annual growth rate) of more than 10%.

Learn More On The Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Report 2023 – https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-developments-and-manufacturing-organization-cmo-global-market-report

Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Size Forecast
The global pharmaceutical contract development and manufacturing organization (CMO) market is expected to grow from $122.31 billion in 2022 to $130.82 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical contract development and manufacturing market is expected to grow from $196.53 billion in 2027 at a CAGR of 10.7%.

North America held the largest pharmaceutical contract development and manufacturing organization (CMO) market share, and Middle East was the fastest-growing region in 2022.

Key Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Driver ­– Increase In The Demand For Medicines Globally
According to Alkermes PLC., a biopharmaceutical company indicates that pharmaceutical contract manufacturing will emerge as a strategic option for many companies ranging from very large to smaller specialty pharma entities and this mostly will happen because the pharmaceuticals companies are looking for cost-cutting.

Request for A Sample Of The Global Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2825&type=smp

Key Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Trend – Merger And Acquisition
The companies in the pharmaceutical contract development and manufacturing market are investing in acquiring and forming alliances with other companies in the market. The pharmaceutical contract development and manufacturing companies are following the trend of merger and acquisition to expand their global market reach to meet the client needs, increase their production capabilities while maintaining cost efficiencies, and get access to the latest technology and new services. The high levels of merger and acquisition activities are resulting in the consolidation of the contract service providers. For instance, in July 2022, Pharma Nobis, a US-based provider of contract manufacturing and private label services, acquired Fagron’s U.S. contract manufacturing business for an undisclosed amount. Through this acquisition, Pharma Nobis is expected to offer contract manufacturing and private label services to American retailers and consumer healthcare corporations. 20% of the company will continue to be owned by Fagron.

Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Segment
1) By Type: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging
2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase I
3) By End-User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small & Medium-Sized Pharmaceutical Companies

Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Major Players and Strategies
Major players in the pharmaceutical contract development and manufacturing organization (CMO) market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH, Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals, HAUPT Pharma AG, Kemwell Pvt. Ltd., Nipro Corp., NextPharma, Royal DSM N.V., Althea Technologies, Thermo Fisher Scientific Inc., Lonza Group Ltd., AbbVie Inc., Consort Medical PLC., Almac Group, Siegfried Holding AG, Evonik Industries AG, and Vetter Pharma International GMBH.

In August 2022, Catalent, Inc., a US-based provider of delivery technologies, development, and drug manufacturing, acquired Metrics Contract Services for $475 million. This acquisition is expected to improve Catalent’s ability to work with highly potent chemicals while enhancing its expertise in integrated oral solid formulation research, production, and packaging to assist clients in streamlining and accelerating their processes. Metrics Contract Services is a US-based pharmaceutical contract development and manufacturing organization.

The Pharmaceutical Contract Development And Manufacturing Organization (CMO) Global Market Report 2023 covers regional data on pharmaceutical contract development and manufacturing organization (CMO) market size, pharmaceutical contract development and manufacturing organization (CMO) market trends and drivers, opportunities, strategies, and pharmaceutical contract development and manufacturing organization (CMO) market competitor analysis. The countries covered in the pharmaceutical contract development and manufacturing organization (CMO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Pharmaceutical contract development and manufacturing refers to a business that offers services for drug research and manufacture within the pharmaceutical sector. Using CDMOs as a partner, pharmaceutical companies can outsource medication development and production. Full-service drug development and manufacturing outsourcing companies (CDMOs) can handle every stage of the process and work with clients that want to outsource specific steps in their workflow. Everything is based on the requirements of each client.

View More Reports Related To The Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market –
Pharmaceutical Drugs Global Market Report 2023
Pharmaceutical Processing Seals Global Market Report 2023
Pharmaceutical Excipients Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: